Intabio, Inc., a Newark, CA-based provider of analytical solutions for biotherapeutic development and manufacturing, raised $9.5m in Series A funding.
The round was led by Northpond Ventures. In conjunction with the funding, Michael P. Rubin, M.D., Ph.D., Founder and CEO at Northpond, joined Intabio’s board of directors alongside seed lead investor, Dr. Jenny Rooke, of Genoa Ventures.
Intabio raised $3.2M in its initial Series Seed financing in 2017. Previous investors included Genoa Ventures and Vertical Venture Partners.
Launched in 2016 by CEO Lena Wu, Ph.D, Intabio provides Blaze™, a platform for biopharma companies to perform a comprehensive analysis of antibody and protein biopharmaceutical products in development, offering higher throughput over traditional methods.
The Blaze system is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications – modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins.